{"id":18847,"date":"2024-09-10T13:25:29","date_gmt":"2024-09-10T17:25:29","guid":{"rendered":"https:\/\/desis.osu.edu\/seniorthesis\/?p=18847"},"modified":"2024-09-23T18:36:33","modified_gmt":"2024-09-23T22:36:33","slug":"neuralink-implanted-a-device-in-a-patients-brain-elon-musk-says","status":"publish","type":"post","link":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/2024\/09\/10\/neuralink-implanted-a-device-in-a-patients-brain-elon-musk-says\/","title":{"rendered":"Neuralink Implanted a Device in a Patient\u2019s Brain, Elon Musk Says"},"content":{"rendered":"\n

“Neuralink, a company working to develop computer interfaces that can be implanted in human brains, placed its first device in a patient on Sunday, said its founder, Elon Musk.<\/p>\n\n\n\n

Mr. Musk, the billionaire chief executive of Tesla and SpaceX, said on Monday that the company\u2019s first product was called Telepathy and would allow a human to control a phone or computer \u201cjust by thinking.\u201d<\/p>\n\n\n\n

\u201cInitial users will be those who have lost the use of their limbs,\u201d Mr. Musk <\/a>wrote in a series of posts on X, his social media platform. \u201cImagine if Stephen Hawking could communicate faster than a speed typist or auctioneer.\u201d<\/p>\n\n\n\n

In November 2022, Mr. Musk predicted that the company would begin tests in humans within six months. At the time, Neuralink demonstrated a product in a video that reportedly showed two monkeys moving computer cursors with their brains, a feat that had been shown to be possible in humans more than 15 years earlier.<\/p>\n\n\n\n

While Mr. Musk is often optimistic with predictions for his companies, some of which have yet to pan out, Neuralink received approval from the Food and Drug Administration to begin human trials last May.<\/p>\n\n\n\n

The company\u2019s website currently says that its \u201cfirst clinical trial is open to recruitment\u201d for people with limited or no use of both hands due to a cervical spinal cord injury or to amyotrophic lateral sclerosis, a neurological disorder that affects nerve cells.<\/p>\n\n\n\n

\u201cThis study involves placing a small, cosmetically invisible implant in a part of the brain that plans movements,\u201d Neuralink\u2019s\u00a0website reads. \u201cThe device is designed to interpret a person\u2019s neural activity, so they can operate a computer or smartphone by simply intending to move \u2014 no wires or physical movement are required\u201d (Mac, 2024).<\/p>\n\n\n\n

It\u2019s possible! The technology is out there and advancing. Musk\u2019s brain implant was approved by the FDA and is bringing its testing within humans. Why does this mean it can\u2019t work within seizure control and also be approved by the FDA. Seeing Elon Musk\u2019s company, Neuralink, if successful, will reach a point where this device can be sold and be profitable. It could be normalized to the same degree as getting an implant in one\u2019s arm as a contraceptive. If this technology is proved to be triumphant, the same technology could be adapted to work within my scope of epilepsy brain implant. Advancing technology is making new futures for people with epilepsy. We can imagine a future with so many less seizures and much happier people. I think it is very probable for the medical community to adapt a similar type of implant in the brain for seizure control and track seizure activity in the brain.<\/p>\n\n\n\n

Reference <\/h2>\n\n\n\n

Mac, R. (2024, January 30). Neuralink implanted a device in a patient\u2019s brain, Elon Musk says<\/em>. The New York Times. https:\/\/www.nytimes.com\/2024\/01\/29\/business\/elon-musk-neuralink.html <\/p>\n","protected":false},"excerpt":{"rendered":"

“Neuralink, a company working to develop computer interfaces that can be implanted in human brains, placed its first device in a patient on Sunday, said its founder, Elon Musk. Mr. Musk, the billionaire chief executive of Tesla and SpaceX, said on Monday that the company\u2019s first product was called Telepathy and would allow a human […]<\/p>\n","protected":false},"author":118,"featured_media":18848,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"class_list":{"0":"post-18847","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/posts\/18847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/users\/118"}],"replies":[{"embeddable":true,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/comments?post=18847"}],"version-history":[{"count":4,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/posts\/18847\/revisions"}],"predecessor-version":[{"id":21965,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/posts\/18847\/revisions\/21965"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/media\/18848"}],"wp:attachment":[{"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/media?parent=18847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/categories?post=18847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/desis.osu.edu\/seniorthesis\/index.php\/wp-json\/wp\/v2\/tags?post=18847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}